...
机译:新型3取代的咪唑和喹唑啉和喹唑啉-4(3H)-ONE衍生物作为PI3Kα抑制剂的设计,合成和生物学评价
School of Traditional Chinese Materia Medica Shenyang Pharmaceutical University;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
College of Pharmacy Seoul National University;
School of Traditional Chinese Materia Medica Shenyang Pharmaceutical University;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
Key Laboratory of Structure-Based Drug Design and Discovery Ministry of Education Shenyang;
Phosphatidylinositol 3-kinase; Imidazo1; 2-apyridine; Quinazolin-4(3H)-one; PIK3CA gene; Anticancer agents;
机译:新型3取代的咪唑和喹唑啉和喹唑啉-4(3H)-ONE衍生物作为PI3Kα抑制剂的设计,合成和生物学评价
机译:咪唑并[1,2-b]哒嗪和咪唑并[1,2-a]吡啶衍生物作为新型双重c-Met和VEGFR2激酶抑制剂的基于结构的设计,合成和评估
机译:新型DPP-4抑制剂咪唑并[1,2-a]吡啶衍生物的设计,合成及生物学评价
机译:咪唑并1,2-c嘧啶衍生物的合成
机译:药物化学中基于结构的药物设计:I.跨病变合成抑制剂的开发II。磺酰哌嗪衍生物对LpxH的抑制作用及其合成及生物学评价
机译:新的二取代的咪唑(吡啶嗪衍生物为选择性HAPIN抑制剂的设计。合成结合模式和抗癌生物学评估
机译:新的二取代的咪唑(吡啶嗪衍生物为选择性HAPIN抑制剂的设计。合成,结合模式和抗癌生物学评估